-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest global cancer burden data released by the World Health Organization's International Agency for Research on Cancer (IARC) in 2020, esophageal cancer is the 8th most common malignant tumor in the world and the 6th leading cause of annual deaths in the world
.
Moreover, esophageal cancer is particularly prominent in China.
According to the World Health Organization's International Agency for Research on Cancer (IARC), esophageal cancer is the 8th most common malignancy in the world and the 6th leading cause of annual deaths
tRNA-derived small RNAs (tsRNAs) are produced in a nuclease-dependent manner in response to various stresses commonly found in cancer
.
The team of Prof.
Recently, the team of Prof.
Zhang Hao from the Medical School of Jinan University published a research paper entitled: A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study in Molecular Cancer .
This prospective clinical study shows that two small RNAs in salivary exosomes, tRNA-GlyGCC-5 and sRESE, can be used as non-invasive biomarkers for the diagnosis and prognosis of esophageal squamous cell carcinoma (ESCC), and also in esophageal squamous cell carcinoma (ESCC).
Determine which patients may benefit from adjuvant therapy before surgery
In this study, the research team first performed RNA sequencing on saliva-derived exosomes from 3 esophageal squamous cell carcinoma (ESCC) patients and 3 healthy controls, identified cancer-enriched small RNAs, and identified cancer-enriched small RNAs in 66 individuals.
further validation in the discovery cohort
.
A multicenter prospective observational study was then conducted using the newly discovered biomarkers in two high-risk areas of esophageal squamous cell carcinoma (ESCC) (320 and 220 individuals, one as a training cohort and one as a validation cohort)
The research team found that a tsRNA (tRNA-GlyGCC-5) and another previously undocumented small RNA (the research team named it sRESE) were found in cancer tissues, cancer cells of patients with esophageal squamous cell carcinoma (ESCC).
and highly enriched in salivary exosomes
.
The dual signature composed of these two small RNAs could distinguish esophageal squamous cell carcinoma (ESCC) patients and controls with high sensitivity (90.
50%) and high specificity (94.
20%)
.
Prognostic risk scores based on this dual feature showed significantly shorter overall survival (OS) and progression-free survival (PFS) in patients with higher risk scores
Collectively, this prospective clinical study showed that a dual signature composed of two small RNAs, tRNA-GlyGCC-5 and sRESE, could serve as a non-invasive biomarker for the diagnosis and prognosis of esophageal squamous cell carcinoma (ESCC) , It is also possible to determine which patients may benefit from adjuvant therapy prior to surgery
.
It is reported that this is also the first clinical trial of salivary exosomal small RNA as a cancer biomarker
A dual signature composed of two small RNAs, tRNA-GlyGCC-5 and sRESE, can serve as a non-invasive biomarker for the diagnosis and prognosis of esophageal squamous cell carcinoma (ESCC) Salivary exosomal small RNAs are the first as cancer biomarkers clinical trials
Original source:
Original source:Li, K.
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study Leave a comment here
